

150 1615



**TRANSMITTAL LETTER**  
**(General - Patent Pending)**

Docket No.  
3407/1/US

In Patent Application Of: Gao et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/047,222	January 15, 2002	Micah Paul Young	26648	1615	5749

Title: **PHARMACEUTICAL COMPOSITIONS HAVING A REDUCED TENDENCY FOR DRUG CRYSTALLIZATION**

COMMISSIONER FOR PATENTS:

Transmitted herewith is:

**Amendment Transmittal; Response to Office Action; Enclosure (3 pgs. Typical Chemical Structures of METHOCEL Products); Itemized Postcard.**

in the above identified application.


- ☒ No additional fee is required.
- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account No. **19-1025** as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**




  
\_\_\_\_\_  
Signature

Dated: June 2, 2005

Patricia K. Fitzsimmons, Reg. No. 52,894  
Pharmacia Corporation of Pfizer Inc.  
P.O. Box 1027  
Chesterfield, Missouri 63006  
314.274.1490

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on June 2, 2005 (Date)  Signature of Person Mailing Correspondence Linda K. Cooper Typed or Printed Name of Person Mailing Correspondence
---

cc:

<b>AMENDMENT TRANSMITTAL LETTER (Large Entity)</b>					Docket No. 3407/1/US	
Applicant(s): Gao et al.						
Application No. 10/047,222	Filing Date January 15, 2002	Examiner Micah Paul Young	Customer No. 26648	Group Art Unit 1615	Confirmation No. 5749	
Invention: <b>PHARMACEUTICAL COMPOSITIONS HAVING A REDUCED TENDENCY FOR DRUG CRYSTALLIZATION</b>						
 <b>COMMISSIONER FOR PATENTS:</b>						
Transmitted herewith is an amendment in the above-identified application.						
The fee has been calculated and is transmitted as shown below.						
<b>CLAIMS AS AMENDED</b>						
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE	
TOTAL CLAIMS	84 -	93 =	0	x \$50.00	\$0.00	
INDEP. CLAIMS	3 -	5 =	0	x \$200.00	\$0.00	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00	
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>					<b>\$0.00</b>	
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account <b>19-1025</b> <input type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17. <input type="checkbox"/> Payment by credit card. Form PTO-2038.						
<b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>						
 _____ <i>Signature</i>			Dated: June 2, 2005			
Patricia K. Fitzsimmons, Reg. No. 52,894 Pharmacia Corporation of Pfizer, Inc. P.O. Box 1027 Chesterfield, Missouri 63006 314.274.1490			<div style="border: 1px solid black; padding: 5px;"> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on</p> <p style="text-align: center;">June 2, 2005 (Date)</p> <p style="text-align: center;">   <i>Signature of Person Mailing Correspondence</i> </p> <p style="text-align: center;">Linda K. Cooper Typed or Printed Name of Person Mailing Correspondence</p> </div>			
cc:						




**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT:	Gao et al.	)	GROUP ART UNIT:	1615
		)		
SERIAL NO.:	10/047,222	)	CONFIRMATION NO.:	5749
		)		
EXAMINER:	Young	)	ATTORNEY DOCKET NO.:	3407/1/US
		)		
FILED:	January 15, 2002	)		
		)		
TITLE:	PHARMACEUTICAL COMPOSITIONS HAVING A REDUCED TENDENCY FOR DRUG CRYSTALLIZATION			

**CERTIFICATE OF MAILING**

I hereby certify that this communication and any recited enclosures are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on **June 2, 2005**.

  
Linda K. Cooper

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

June 2, 2005

**RESPONSE TO OFFICE ACTION**

Sir:

In response to the Office action of March 3, 2005, please consider the following remarks.

Claims 1-5, 8-29, 31-40, 43-63, 65-70, and 72-91 are currently pending. Applicants note that the Office action states that claims 1-91 are pending. This is incorrect. Claims 6, 7, 30, 41, 42, 64, and 71 were cancelled in the Amendment filed October 18, 2004.

**Provisional non-statutory double patenting rejection**

Reconsideration is respectfully requested of the provisional rejection of claims 1, 2, 4, 5, 8-16, 20-27, 31-37, 43-45, 48-50, 54-57, 60, 61, 65-70, 72-75, and 84-91 under the doctrine of obviousness-type double patenting as unpatentable over claims 1-12, 19-20, and 24-32 of copending U.S. Application No. 10/119,118 (Atty. Docket No. 3406/2/US).